Amodiaquine - sulfadoxine + pyrimethamine

EMLc | ATC codes: P01BA06 P01BD51

Indication	Malaria ICD11 code: 1F4Z
INN	Amodiaquine + sulfadoxine + pyrimethamine
Medicine type	Chemical agent
List type	Core
Formulations	**Oral > Solid > dispersible tablet:** 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc) ; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc)
EML status history	First added in 2019 (TRS 1021) Changed in 2025 (TRS 1064)
Sex	All
Age	Children (1 month - 12 years)
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents.
Wikipedia	Amodiaquine - sulfadoxine + pyrimethamine
DrugBank	Amodiaquine, Sulfadoxine, Pyrimethamine

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strengths of co-packaged amodiaquine with sulfadoxine + pyrimethamine to the EMLc for seasonal malaria chemoprevention in children.